b7h3 cd276 a target for antibody drug conjugates adcs and protacs in advanced prostate cancer clinical trial intelligence

An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

QLC5508 and QLH12016 are being evaluated in combination with established therapies (abiraterone and enzalutamide) for advanced prostate cancer, a significant market with unmet needs. The trial's dual-phase design allows for both safety and efficacy exploration, potentially positioning Qilu Pharmaceutical Co., Ltd. favorably against competitors in the prostate cancer treatment landscape. The study's focus on patients who have failed standard therapies may enhance the asset's appeal in a crowded market. Successful outcomes could lead to accelerated development timelines and increased investor interest, particularly given the rising prevalence of prostate cancer globally.

Matched by target_normalized: B7H3 (CD276) - a target for antibody-drug conjugates (ADCs) and PROTACs in advanced prostate cancer.